Shots:
- Halozyme Therapeutics, via its subsidiary Halozyme Hypercon, has entered a global exclusive collaboration & license agreement with Vertex to utilize its Hypercon technology across up to three drug targets
- As per the deal, Halozyme will receive $15M upfront, with additional milestone payments & royalties tied to products developed using the technology
- Hypercon is a microparticle-based platform that enables drug hyperconcentration, reducing injection volume while supporting convenient at-home administration of biologics
Ref: PRnewswire | Image: Halozyme & Vertex | Press Release
Related News: Merus Partners with Halozyme to Develop Subcutaneous Petosemtamab
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
